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Nanoparticle transport through the blood-brain barrier has
received much attention of late, both from the point of view
of nano-enabled drug delivery, as well as due to concerns
about unintended exposure of nanomaterials to humans and
other organisms. In vitro models play a lead role in efforts to
understand the extent of transport through the blood-brain
barrier, but unique features of the nanoscale challenge their
direct adaptation. Here we highlight some of the differences
compared to molecular species when utilizing in vitro blood-
brain barrier models for nanoparticle studies. Issues that may
arise with transwell systems are discussed, together with
some potential alternative methodologies. We also brieﬂy
review the biomolecular corona concept and its importance
for how nanoparticles interact with the blood-brain barrier.
We end with considering future directions, including indirect
effects and application of shear and ﬂuidics-technologies.
Introduction
Nanoparticles of increasingly sophisticated variations are find-
ing one of their most important applications as drug delivery
vehicles.1-4 Because of their size, they may accumulate passively
in tumors through the Enhanced Permeability and Retention
(EPR) effect5,6 and thereby deliver anti-cancer drugs.7,8 In addi-
tion, their highly modifiable surface allows decoration with bind-
ing motifs from antibodies, proteins or small peptides, and thus a
potential means for achieving selective attachment to malignant
cells (active targeting). Nanoparticles are also showing promise
for delivering therapeutics against diseases in the central nervous
system,9-12 such as Alzheimer and Parkinson diseases or acquired
immunodeficiency syndrome (AIDS). The central nervous sys-
tem is one of the most challenging locations to reach, mainly due
to the protective effect stemming from the blood-brain bar-
rier.12,13 Nevertheless, nanoparticles are in general rapidly taken
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as transferrin,17,18 apolipoprotein E,19-23 RVG2924 or Angio-
peps25 it is hoped that a well-regulated uptake into the blood-
brain barrier can be reached, and subsequently a concomitant
transport across it.
On the other hand, the increased usage of nanotechnologies in
consumer products have also called for consideration of whether
there are any unforeseen hazards if nano-sized objects are exposed
to human beings.26-31 Naturally, passage into the brain, and
potential subsequent effects, is of particular importance in this
arena.32 Early studies have, in fact, shown nanoparticles in the
brain of rats after inhalation exposure,33,34 though the transloca-
tion likely occurred via the olfactory nerve,33 rather than across
the blood-brain barrier.
Central to determining if, and via what mechanisms, nano-
particles pass the blood-brain barrier remain in vitro models.
Naturally, there will always be the question of how accurate in
vitro models represent the in vivo situation. Nevertheless, due to
their ease of working, in vitro models offer distinct advantages.
This is particularly so when it comes to identifying mecha-
nisms,35 even if final validation will, perhaps, always have to be
done in vivo. While in vitro blood-brain barrier models have
been applied for a long time for the transport of molecular com-
pounds, several, rather unique, features of the nanoscale chal-
lenge their direct adaptation to nanoparticle transport – from a
quantitative, but even a qualitative, point of view. It is the pur-
pose of this text to highlight some of the differences compared to
molecular species. We start by discussing the application of trans-
well systems to nanoparticle transport across in vitro blood-brain
barrier models and the many issues that may arise, particularly
when it comes to quantitative measurements. Next, we propose
alternative methodologies which could alleviate the issues. We
continue with a brief review of the concept of the biomolecular
corona, another prime difference between nanoparticles and
molecular species. Finally, we end with considering potential
implications and an outlook toward the future.
Application of transwell systems to nanoparticle
transport
Transwell systems
The “classical” approach to measure transport across the
blood-brain barrier, or barriers in general, is by utilizing (some
form of) transwell system (Fig. 1). Briefly, the barrier is grown
on a support filter which separates 2 different compartments.
The filter is porous, thus allowing transport through it, at least in
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principle. The choice of support filter is important, both for
ensuring the formation of a good barrier and potentially to allow/
minimize (depending upon application) cell migration through
the filter, but will not be covered here. Once a barrier has formed,
transport through the barrier of a molecule/nanoparticle is mea-
sured by replacing the solution in the upper compartment with
one including the object of interest. Subsequently, the amount
that has transported through to the lower compartment is mea-
sured, e.g., by sampling the lower compartment and analyzing it
optically, radioactively or using mass spectrometry. Based upon
the amount in the lower chamber, the transport through the bar-
rier is then quantified,36 e.g., in terms of a permeability coefficient.
This methodology has a long history and, while there may of
course be technical complications in specific cases, is well-estab-
lished as a general tool for measuring transport of molecular spe-
cies. However, several issues arise when applying the same
methodology to the transport of nanoparticles across barriers
(Fig. 2). Some of these issues are not novel for nanoscale objects
(e.g., imperfections of the barriers) but would appear to be more
severe for assessing transport of nanoparticles; some of the issues
(e.g., agglomeration) are, on the other hand, rather unique for
particles.
Nanoparticle agglomeration and adherence to filter
An issue with a distinct particle characteristics is agglomera-
tion of the particles (Fig. 2A).37 This could potentially occur at
any point along the transport: in the upper compartment, inside
cells, in the filter membrane or in the lower compartment. Nano-
particle agglomeration in the upper compartment, i.e., if the
nanoparticles agglomerate already in the medium in which they
are exposed to cells, is a serious issue. From the simplest point of
view, it implies that the nanoparticles that are actually delivered
to the cells are quite different from the pristine particles that the
experiment set out to investigate. E.g., if 50 nm nanoparticles
agglomerate to form dimers, then it is these larger dimers that
reach the cells, and their transport rate through the barrier may
be rather different from the original particles. More importantly,
agglomeration is typically uncontrolled, and it is unlikely that
such a thing as a suspension of only dimers were actually to form
in practice. Rather, agglomeration is more likely to result in a
heterogeneous dispersion, including everything from single par-
ticles to larger agglomerates. In addition, due to the uncontrolled
nature of agglomeration, the characteristics of the dispersion may
be different each time it is prepared, implying a poor basis for
reproducibility. Furthermore, nanoparticle concentrations used
in vitro would typically far exceed realistic in vivo doses, and since
agglomeration is concentration-dependent, this implies that the
suspension tested in vitro may have little to do with the one actu-
ally used in vivo. In essence, nanoparticles which agglomerate in
the cell medium are better not used.
Agglomeration inside cells is a completely different issue,
because, if it takes place, it is a genuine process not having to do
with idiosyncrasies of experimentation. Even if nanoparticles
were to be taken up by cells individually, it is expected that they
will gather in the same organelles intracellularly (e.g., in sorting
endosomes). Indeed, nanoparticle clusters in organelles have
been observed in several different cell types,38,39 including in in
vitro blood-brain barrier models.40,41 Whether these nanoparticle
Figure 1. Transwell system applied to measure the transport of nanopar-
ticles across in vitro blood-brain barriers. A porous membrane, upon
which the in vitro blood-brain barrier model is grown, separates two
compartments. The nanoparticles are added to the upper compartment,
and the number of nanoparticles that passes through to the lower com-
partment is measured.
Figure 2. Potential issues with applying transwell systems to measure
the transport of nanoparticles across in vitro blood-brain barriers.
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clusters are actually agglomerates (in the colloid science meaning
of the word) or just several nanoparticles in the same organelle is
not clear, but certainly there is the possibility for actual agglomer-
ation. Agglomeration may affect the assessment of transport in
several ways. The quantification of the number of nanoparticles
in the lower chamber is one. For instance, if the number of nano-
particles in the lower compartment is quantified in terms of fluo-
rescence, then the measured fluorescence has to be converted to
number (concentration) of nanoparticles. However, the relation
between fluorescence and number (concentration) of nanopar-
ticles is affected by agglomeration of the particles, and there is
really no adequate way of predicting the effect, nor of calibrating
for it experimentally.
A different issue concerns transport through the porous sup-
port membrane. Obviously, the basic assumption behind the
transwell set-up is that transport through the cell barrier is vastly
slower than transport through the support membrane. However,
several issues may reduce transport through the support mem-
brane, and invalidate this assumption for nanoparticles. In severe
cases, the nanoparticles may form large agglomerates as they
transport through the cell barrier, and these agglomerates may be
too large to pass through the pores of the support filter, especially
if the particles are solid and non-deformable. The nanoparticles
may also adhere to the pore walls of the filter (Fig. 2B),41 making
passage more difficult for nanoparticles which do not adhere, or
causing agglomeration inside the pores of the filter, which will
further obstruct transport.
Imperfections of the barrier
While in vivo the (healthy) blood-brain barrier forms one con-
tinuous structure, it is difficult to imagine that the same can be
achieved in vitro. Certainly much can be done in terms of the
choice of cell model, the choice of membrane support and in
optimising growth conditions. Nevertheless, it is likely that there
will always remain some imperfections, on a macroscopic scale.
One example is areas where cells grow on top of each other to
form bilayers, or even multilayers (Fig. 2C).40 With optimised
conditions, this should not be very frequent, but may still occur.
The presence of bi- or multilayers would be expected to impede
transport through the cell barrier, which obviously would make
the barrier appear to transport slower than it actually would in
vivo. Nevertheless, this is a quantitative effect and would – in iso-
lation – probably give at least the correct qualitative picture.
The presence of holes in the barrier is more severe. Holes may
be rather large (Fig. 2D), as in areas of the barrier where cells are
“simply missing,” or holes due to adjacent cells being too distant
to adhere to each other, but where there is nevertheless not
enough space to “fit” a full extra cell. At a more microscopic level,
tight junction formation may not be completely perfect through-
out the whole barrier, again resulting in holes in the barrier
(Fig. 2E). These holes may be too small to observe using (classi-
cal) optical microscopy, where the diffraction limit sets the lower
limit on what can be resolved, and difficult to find using electron
microscopy, which can only investigate limited areas. The prob-
lem with holes in the barrier is that even if they are not very prev-
alent, they can still have a large effect.40 The essential
complication is that transport of nanoparticles through actual
cells is so slow, and transport through holes so rapid, that the
contribution from transport through holes can easily mask the
transport through cells (a back-of-the-envelope estimate is illus-
trated in ref. 40). This would – even in itself – prevent not only
quantitative, but also qualitative measurements. For example, if
comparing the transport of two types of nanoparticles, one could
hope to subtract (or adjust for) the transport through the holes,
and still gain a qualitative assessment of which type of nanoparti-
cle exhibits the most rapid transport. However, if transport
through the holes is dominating the whole transport process,
then what remains after the subtraction is essentially “noise,” and
cannot be used even for a qualitative estimate.
The severity of the different issues becomes worse when con-
sidered as a whole, because the different issues will affect trans-
port in different ways: adherence to pore walls of the support
filter lowers transport, while holes in the barrier will increase it.
Basically, it is difficult to know, without auxiliary observations, if
a measurement is over- or underestimating the actual transport.
Methodologies for improved quantiﬁcation of
nanoparticle transport across in vitro blood-brain
barrier models
Given the difficulty in using classical methods to measure –
even qualitatively – nanoparticle transport through in vitro
blood-brain barrier models, it is important to discuss alternatives.
Some of the issues can be circumvented by a different choice of
detection method. For example, the quantification of the number
of nanoparticles in the lower compartment may be confounded
due to agglomeration of the nanoparticles (inside cells or in the
support membrane). This is an issue if the number of nanopar-
ticles is quantified using fluorescence, but can be circumvented if
the quantification is performed using other techniques, e.g.,
Inductively Coupled Plasma Resonance Mass Spectrometry (ICP
MS),42 potentially employing isotopic labeling,43 or radioactive
labeling44 and detection. Furthermore, if the number of nanopar-
ticles inside the support membrane is included in the quantifica-
tion,42 then the adherence to filters may be less of an issue.
The transport through holes in the barrier is probably the
worst complication, even if the holes are not very abundant.40
Qualitative information could potentially be gained using elec-
tron microscopy, which in fortunate cases can catch events of
transcytosis on the basal side of the barrier.40,42 Naturally, this
can also be used to gain qualitative information in vivo, as has
indeed already been done.21,45,46 Still, the area of the barrier that
can be covered using electron microscopy is limited, which pre-
cludes a quantitative estimate. Furthermore, even in the case
where a nanoparticle is found at the basal membrane of an in
vitro blood-brain barrier, inside an “evagination,” it is still possi-
ble that the nanoparticle is actually entering, rather than exiting,
the cell – from the basal side.40 The nanoparticle could have
arrived at the site of entry by traveling underneath the barrier,
originally accessing the basal side from a hole in the barrier. This
may not be apparent, because the hole in the barrier could be out
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of sight in the image which shows the nanoparticle entering,
given the thinness of electron microscopic sectioning. Obviously,
such issues are aggravated by the limited area that can be (swiftly)
covered by electron microscopy. They also inhibit approaching
the question of nanoparticle transport through the barrier using
quantitative electron microscopy,47 unless the probability of find-
ing a hole can somehow be adjusted for.
An alternative solution may be sought in live-cell imaging, as
we have recently advocated.40 The main advantages are, first, that
holes in an in vitro blood-brain barrier (at least those larger than
the optical diffraction limit) can explicitly be looked for.
Thereby, if there is a hole in one particular field of view, then
this part of the barrier need not be further investigated. Second,
both the transport across the barrier, and the barrier itself, can be
followed – in real time. Thus, it is possible to differentiate if a
nanoparticle arrives at the basal side of a cell in the barrier by
traveling underneath the cells, originally from a hole in the bar-
rier, or of it exits from a cell. Furthermore, the integrity of the
barrier can be followed in time, and in this way it is possible to
identify the potential formation of transient holes in the barrier.
Naturally, this whole approach is only applicable to fluorescent
nanoparticles, though one could imagine using it with correlative
microscopy.48 A second disadvantage is that it demands some-
what extensive imaging work, and subsequent image analysis.
This could, however, be sidestepped using high-content analysis
and automated, or semi-automated, image analysis.
The biomolecular corona and its role in
nanoparticle transport across the blood-brain
barrier
The biomolecular corona
A different aspect – which clearly distinguishes nanoparticles
from molecular species – of importance for how nanoparticles
transport through the blood-brain barrier is the concept of bio-
molecular corona.49,50 The biomolecular corona refers to the
adsorption of biomolecules from the environment onto the nano-
particle, forming a “corona” of biomolecules (Fig. 3A) that cov-
ers the original nanoparticle surface (Fig. 3B). The formation of
such a corona is important to consider, because in any imaginable
way a nanoparticle would come in contact with the blood-brain
barrier in vivo, it would do so in the presence of a complex mix-
ture of biomolecules in its environment, all of which could
potentially adsorb. Indeed, proteins,49,51,52 lipids53-56 and sug-
ars57,58 have all been found in the corona of different nanopar-
ticles in animal-derived biological media, though the proteins are
still the most studied. Furthermore, though which biomolecules
adsorb differs, the same general phenomenon of a formation of
corona is observed in many biological fluids,59 from blood
serum50,52,60,61 to bronchoalveolar lavage fluid56 to urine.59 For
nanoparticles approaching the blood-brain barrier, the corona
formed in blood serum is perhaps the most important (but not
the only; see below) to consider, and this is also the most well-
studied.
It is a characteristic of the nanoscale, that the adsorption of
biomolecules to nanoparticles can be so strong that (some of the)
biomolecules will remain with the nanoparticle for much longer
than it takes a cell to take up the nanoparticle.61-64 This is partic-
ularly so for metal,64 metal oxide61,62 and other inorganic nano-
particles.62,63 Still, biomolecular adsorption is sometimes also
observed for nanoparticles intended as medicines, e.g., those with
grafted ligands, even if PEGylated to prevent unspecific adsorp-
tion.65-68 Effectively what it means is that, the original nanoparti-
cle surface is not seen by the cell membrane, but rather those
biomolecules which remain on the nanoparticle surface for long
enough. Thus, cell membrane receptors will interact with biomo-
lecules in the corona, and, presumably, this interaction will deter-
mine by which mechanism the nanoparticle enters the cell.69,70
Subsequently, one would hypothesize that once inside, the bio-
molecules in the corona – if, indeed, the remain associated with
the nanoparticle71-73 – will determine to where the nanoparticle
is shuttled, including if it is sent through to the other side of the
barrier. This puts the spotlight on identifying which biomole-
cules are found in the corona, and which remain there for long
times. It is noteworthy that the corona composition is not a sim-
ple reflection of the biofluid in which the nanoparticle is found.
That is, if a nanoparticle is put into blood plasma with serum
albumin as its main component, this does not imply that serum
albumin is the main component of the nanoparticle corona.49
Rather, low abundant species are frequently picked up by nano-
particles, and, in general, the corona depends strongly on nano-
particle properties such as surface,74 size,61,74 shape75 and even
concentration of the biofluid.60
Importance in vivo
It seems clear that the corona will be a key determinant of how
the nanoparticles are processed in vivo. In a sense, this has already
been partly demonstrated. Thus, coating nanoparticles by poly-
sorbate 80 results in the adsorption of apolipoproteins to the
nanoparticle surface10,76 – in the language employed here, the
formation of a corona which includes apolipoproteins – and this
has been related to successful transport of a drug across the
Figure 3. Role of biomolecular corona in nanoparticle interactions with
the blood-brain barrier. (A) Corona-covered nanoparticle interacting
with cells of the barrier vs. (B) bare nanoparticle. Only the former situa-
tion is expected to occur in vivo.
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blood-brain barrier.77 Whether the nanoparticle transports
across, or is retained in the blood-brain barrier, however remains
unclear.11
It is important to stress that the corona is not a reflection only
of the current environment, but rather exhibits history depen-
dence.49,78 That is, some biomolecules may remain for very long
times in the corona, while others may be exchanged if the exter-
nal environment is changed. Thus, one may potentially observe
very different coronae on nanoparticles reaching the blood-brain
barrier via different exposure routes – even for the same nanopar-
ticle. For example, if a nanoparticle is intravenously injected it
may only have seen blood before reaching the blood-brain bar-
rier, and the composition of the corona will reflect that. On the
other hand, if the same nanoparticle is inhaled, it may first be
exposed to lung-lining fluid, then transfer through the pulmo-
nary barrier, before being exposed to blood and reach the blood-
brain barrier.32 Some of the biomolecules picked up in the lung
may remain, some will have been displaced upon transfer
through the pulmonary barrier and others will adsorb in blood.
Such effects may, ultimately, justify potential differences in how
nanoparticles are processed by the blood-brain barrier depending
upon the exposure route.32
In vitro considerations
The corona has immense importance for in vitro experimenta-
tion on blood-brain barrier models. It is clear that if one wants to
perfectly mimic the in vivo situation, then imitation of how the
nanoparticle reached the blood-brain barrier is needed. In the
simplest case of an intravenously injected nanoparticle, this
would imply exposing the nanoparticle to an in vitro blood-brain
barrier in the presence of blood plasma. For inhaled nanopar-
ticles, on the other hand, this could imply mimicking how the
nanoparticle interacted with lung-lining fluid, transferred
through the pulmonary barrier and finally found itself in blood
before reaching the blood-brain barrier. In principle this can be
done, with some fidelity, by successively exposing the nanoparti-
cle to different biofluids, for the correct period of time, before
exposing it to the blood-brain barrier model. More subtle issues
concern the concentration of the biofluid,79 and potentially spe-
cies differences (including adaptation),49,79 i.e., matching of the
species origin of the cell type with the origin of the biofluid.
However, even if one does not want to perfectly mimic the in
vivo situation, the overall presence of a corona is crucial. In the pres-
ence of a corona, nanoparticles are taken up by cells in a regulated
manner, entering cells via energy-dependent processes14-16 and fol-
lowing endogenous sorting pathways inside cells.14,16 In the absence
of a corona, on the other hand, nanoparticles have been observed to
enter cells passively, breaking the cell membrane in the process, and
subsequently diffusing around the cell cytosol.80 Similarly, cell
death has also been associated with lack of corona.73,80-82 These
observations may be justified in terms of the high surface energy of
the nanoparticle surface.83 In the presence of biomolecules, the
high surface energy is lowered by the adsorption of biomolecules
and corona formation. Subsequent interactions with cells “occur at
a lower energy scale,” and endogenous processing takes place. In the
absence of biomolecules, on the other hand, the high surface energy
of the original nanoparticle surface remains when in contact with
cells. Thus, components from the cell membrane instead adsorbs to
the nanoparticle – effectively forming a cell-derived corona80 – and
only then is the high surface energy lowered. In essence, it is impera-
tive to expose nanoparticleswith corona to blood-brain barrier mod-
els, because otherwise effects that will never be seen in vivo may be
observed. Corona formation can be ensured simply by using
medium supplemented with serum (or, better yet, plasma) in the
nanoparticle studies. This may not be the correct corona, because
the exposure route will determine which biomolecules can be found
in the corona, and ultimately those biomolecules will determine
how the nanoparticle is processed by the blood-brain barrier. Never-
theless, while the detailed biomolecules will determine the specifics,
it would appear that a far bigger effect results from having biomole-
cules there at all.
Implications and outlook
Indirect effects
In a related arena, Case and colleagues have made the interest-
ing observation that nanoparticles can cause signaling across cell
barriers – without actually passing through the barrier.84,85 Such
indirect effects have actually been observed also for the blood-
brain barrier (Fig. 4), with signaling taking place between an in
vitro blood-brain barrier and astrocytes grown below it.86 It is
obviously imperative that studies on indirect effects are carried
out with many of the issues discussed here in mind. For instance,
if in vivo a nanoparticle is able to exert an indirect effect across
the blood-brain barrier, but in vitro crosses an imperfect blood-
brain barrier through holes in the barrier, what is actually an indi-
rect effect could be misinterpreted as a direct effect. Obviously
the opposite could also occur. One could imagine even more
complicated scenarios, where in vivo signaling takes place but not
to a significant extent, whereas the nanoparticle passes through
holes in an imperfect barrier, picks up the signaling molecule on
the other side of the barrier through adsorption, and subse-
quently delivers it to the receiving cells, at a higher dose. Such
variations on the “trojan horse” effect87 could be a significant
challenge to dissect, if imperfections in the barrier are not
considered.
Application of shear stress
One of the more important elements missing from in vitro
blood-brain barrier models, at least in their present typical incar-
nation, is shear stress on the cells. This may be an area where
more attention is needed in future, for two reasons: First, applica-
tion of shear stress may improve the quality of in vitro blood-
brain barriers. Thus, it has been shown that shear stress changes
the expression of a large number of genes in endothelial cells,88,89
and also that tight junction formation is promoted in an
in vitro blood-brain barrier model.90 Such observations suggest
that more well-defined in vitro blood-brain barrier models may
be achievable by applying shear stress. Conversely, it is imperative
to ensure that imperfections are not introduced by applying shear
stress, e.g., due to the flow “washing away” cells, thus leaving the
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barrier with holes in it. Second, the adaptation to shear stress
could also directly affect how cells of the blood-brain barrier take
up and subsequently transport the nanoparticle. Indeed, nano-
particle uptake into barriers has been shown to be affected by
application of shear in in vitro systems,91-93 and there are also
theoretical arguments to support such reports.94,95
Fluidics and miniaturization
The general adaptation of microfluidics as a methodology96
could prove to be a significant factor in advancing knowledge on
nanoparticle transport across the blood-brain barrier. Due to the
smaller areas involved, it may be possible to form much
improved barriers, without holes and other imperfections. Cou-
pled to the possibility of continuous, and well-defined, shear
stress, this could give much refined in vitro “brain-on-a-chip” sys-
tems. Looking further into the future, it is conceivable that
researchers could move beyond even that. Above it was discussed
how the nanoparticle biomolecular corona potentially could
depend upon the exposure route, exemplified by an intravenously
injected nanoparticle or one reaching the blood-brain barrier
through inhalation. The latter process may be possible to mimic
– a “human-body-on-a-chip” approach97 – using coupled fluid
reservoirs representing the different environments and letting the
nanoparticles pass these reservoirs in succession before finally
arriving to an in vitro blood-brain barrier model.
Following nanoparticles through the barrier, in detail
Whether for improving therapeutic delivery of nanomedicines
against neurodegenerative disorders, or whether out of concern
for eventual hazards posed by nanoparticles passing into the
brain, vital for the future will be to understand what nanoparticle
properties enable efficient uptake into and transport across the
blood-brain barrier. Knowing the most important properties will
enable engineering the nanoparticles so as to avoid unwanted
accumulation (in the latter case) or optimise desired accumula-
tion into the brain (in the former). Likely in vitro blood-brain
barrier systems will play a lead role in this effort, because they
enable a much more rapid, economical and ethical screening of
nanoparticle properties than does in vivo experimentation. Ulti-
mately, it may be necessary to dissect the full transport pathway
through the cells, from the early endocytic events, via the sorting
stage and to the eventual transcytic event. If no simple correlation
between nanoparticle properties (including their biomolecular
coronae) and transport efficiency can be found, then this is likely
the only option available in order to understand what facilitates,
or impedes, efficient transport through the barrier. In vitro mod-
els “will be key in this endeavor” because they allow observing
each event as it happens – live – and thereby to build knowledge
of each step encountered by nanoparticles on their way through
the blood-brain barrier.
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